Health Care • Biotechnology: Pharmaceutical Preparations
$3.74 ▼ -0.07
(-1.84%)
MKT CAP: $106.1M • VOL: 1.30M
52W L $3 52W H $9
ROARABLE / RQD
D • 45/100
PIOTROSKI
2 / 9
UNCY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $675.0K |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$29.5M | -$32.1M | -$20.8M |
| Operating Margin % | — | — | -80.0% |
| Net Income (GAAP) | -$26.6M | -$36.7M | -$30.5M |
| EBITDA (Normalized) | -$29.5M | -$32.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$31.3M | -$28.6M | -$18.3M |
| Capital Expenditures (CapEx) | $24.0K | $72.0K | — |
| Free Cash Flow (FCF) | -$31.3M | -$28.6M | -$18.3M |
| FCF Margin % | — | — | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $29.2M | $26.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $30.2M | $7.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR UNCY.